(Q43176322)

15 November 2017

title

Similarity in pharmacokinetics of oseltamivir and oseltamivir carboxylate in Japanese and Caucasian subjects (English)

1 reference

15 November 2017

1 reference

1 reference

4

Craig R Rayner

1 reference

15 November 2017

1

Jerome J Schentag

1 reference

15 November 2017

George Hill

2

1 reference

15 November 2017

Tom Chu

series ordinal

3

1 reference

15 November 2017

publication date

24 April 2007

1 reference

The Journal of Clinical Pharmacology

15 November 2017

published in

1 reference

15 November 2017

volume

47

1 reference

15 November 2017

issue

6

1 reference

15 November 2017

page(s)

689-696

1 reference

Influenza: vaccination and treatment.

15 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0091270007299761

Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007299761

Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007299761

Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007299761

Effectiveness of oseltamivir treatment against influenza type A and type B infection in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007299761

Oral oseltamivir treatment of influenza in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007299761

Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007299761

Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007299761

Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007299761

Long-term use of oseltamivir for the prophylaxis of influenza in a vaccinated frail older population

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007299761

A multicentre, randomized, controlled trial of oseltamivir in the treatment of influenza in a high-risk Chinese population

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007299761

Use of Oseltamivir to control influenza complications after bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007299761

Safety and pharmacology of oseltamivir in clinical use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007299761

Pharmacokinetics and dosage recommendations for an oseltamivir oral suspension for the treatment of influenza in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007299761

Pharmacokinetics of anti-influenza prodrug oseltamivir in children aged 1-5 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007299761

The pharmacokinetics and tolerability of the oral neuraminidase inhibitor oseltamivir (Ro 64-0796/GS4104) in healthy adult and elderly volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007299761

Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007299761

Pharmacokinetics of oseltamivir in young and very elderly subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007299761

Lack of effect of moderate hepatic impairment on the pharmacokinetics of oral oseltamivir and its metabolite oseltamivir carboxylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007299761

Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007299761

Pharmacogenomic assessment of carboxylesterases 1 and 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007299761

Pharmacogenetics of human carboxylesterase 2, an enzyme involved in the activation of irinotecan into SN-38

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007299761

Determination and analysis of single nucleotide polymorphisms and haplotype structure of the human carboxylesterase 2 gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007299761

The anti-influenza drug oseltamivir exhibits low potential to induce pharmacokinetic drug interactions via renal secretion-correlation of in vivo and in vitro studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007299761

Pharmacogenomics of the OATP and OAT families

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007299761

Functional analysis of polymorphisms in the organic anion transporter, SLC22A6 (OAT1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007299761

Functional consequences of single nucleotide polymorphisms in the human organic anion transporter hOAT1 (SLC22A6).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007299761

Resistant influenza A viruses in children treated with oseltamivir: descriptive study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007299761

21 January 2018

Identifiers

DOI

10.1177/0091270007299761

1 reference

15 November 2017

1 reference